Intravitreal ziv-aflibercept for macular edema following retinal vein occlusion
Remya Paulose,1 Jay Chhablani,1 Chintan J Dedhia,1 Michael W Stewart,2 Ahmad M Mansour3,4 1Smt. Kanuri Santhamma Centre for Vitreoretinal Diseases, LV Prasad Eye Institute, Hyderabad, India; 2Department of Ophthalmology, Mayo Clinic, Jacksonville, FL, USA; 3Department of Ophthalmology, American Uni...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2016-09-01
|
Series: | Clinical Ophthalmology |
Subjects: | |
Online Access: | https://www.dovepress.com/intravitreal-ziv-aflibercept-for-macular-edema-following-retinal-vein--peer-reviewed-article-OPTH |
id |
doaj-d46c2e2c7cbf4185b6133259e5049e92 |
---|---|
record_format |
Article |
spelling |
doaj-d46c2e2c7cbf4185b6133259e5049e922020-11-25T00:25:28ZengDove Medical PressClinical Ophthalmology1177-54832016-09-01Volume 101853185829061Intravitreal ziv-aflibercept for macular edema following retinal vein occlusionPaulose RChhablani JDedhia CJStewart MWMansour AMRemya Paulose,1 Jay Chhablani,1 Chintan J Dedhia,1 Michael W Stewart,2 Ahmad M Mansour3,4 1Smt. Kanuri Santhamma Centre for Vitreoretinal Diseases, LV Prasad Eye Institute, Hyderabad, India; 2Department of Ophthalmology, Mayo Clinic, Jacksonville, FL, USA; 3Department of Ophthalmology, American University of Beirut, 4Department of Ophthalmology, Rafic Hariri University Hospital, Beirut, Lebanon Aim: To report the efficacy of intravitreal ziv-aflibercept injections in eyes with macular edema due to retinal vein occlusions (RVOs). Methods: Consecutive patients with persistent or recurrent macular edema (central macula thickness >250 µm) due to RVO were enrolled in this prospective study. Study eyes received intravitreal injections of ziv-aflibercept (1.25 mg/0.05 mL) at baseline. Patients were reassessed monthly for 4 months and given additional injections pro re nata for worsening best-corrected visual acuity (BCVA), intraretinal edema or subretinal fluid seen on spectral domain optical coherence tomography, or central macular thickness (CMT) measurements >250 µm. The primary endpoint was improvement in mean CMT at 4 months. Secondary endpoints included improvement in mean BCVA, and ocular and systemic safety signals. Results: Nine eyes (five central and four branch RVOs) of nine patients were enrolled. The mean ± standard deviation CMT decreased from 604±199 µm at baseline to 319±115 µm (P=0.001) at 1 month and to 351±205 µm (P=0.026) at 4 months. The mean BCVA did not improve significantly from baseline (1.00 LogMAR) to the 1-month (0.74 LogMAR; P=0.2) and 4-month (0.71 LogMAR; P=0.13) visits. No safety signals were noted. Conclusion: In this small prospective study, intravitreal ziv-aflibercept significantly improved mean CMT in eyes with persistent or recurrent macular edema due to RVOs. Prospective, randomized trials comparing ziv-aflibercept with standard pharmacotherapy are needed to better define efficacy and safety. Keywords: ziv-aflibercept, retinal vein occlusion, cystoid macular edemahttps://www.dovepress.com/intravitreal-ziv-aflibercept-for-macular-edema-following-retinal-vein--peer-reviewed-article-OPTHziv-afliberceptretinal vein occlusioncystoid macular edema |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Paulose R Chhablani J Dedhia CJ Stewart MW Mansour AM |
spellingShingle |
Paulose R Chhablani J Dedhia CJ Stewart MW Mansour AM Intravitreal ziv-aflibercept for macular edema following retinal vein occlusion Clinical Ophthalmology ziv-aflibercept retinal vein occlusion cystoid macular edema |
author_facet |
Paulose R Chhablani J Dedhia CJ Stewart MW Mansour AM |
author_sort |
Paulose R |
title |
Intravitreal ziv-aflibercept for macular edema following retinal vein occlusion |
title_short |
Intravitreal ziv-aflibercept for macular edema following retinal vein occlusion |
title_full |
Intravitreal ziv-aflibercept for macular edema following retinal vein occlusion |
title_fullStr |
Intravitreal ziv-aflibercept for macular edema following retinal vein occlusion |
title_full_unstemmed |
Intravitreal ziv-aflibercept for macular edema following retinal vein occlusion |
title_sort |
intravitreal ziv-aflibercept for macular edema following retinal vein occlusion |
publisher |
Dove Medical Press |
series |
Clinical Ophthalmology |
issn |
1177-5483 |
publishDate |
2016-09-01 |
description |
Remya Paulose,1 Jay Chhablani,1 Chintan J Dedhia,1 Michael W Stewart,2 Ahmad M Mansour3,4 1Smt. Kanuri Santhamma Centre for Vitreoretinal Diseases, LV Prasad Eye Institute, Hyderabad, India; 2Department of Ophthalmology, Mayo Clinic, Jacksonville, FL, USA; 3Department of Ophthalmology, American University of Beirut, 4Department of Ophthalmology, Rafic Hariri University Hospital, Beirut, Lebanon Aim: To report the efficacy of intravitreal ziv-aflibercept injections in eyes with macular edema due to retinal vein occlusions (RVOs). Methods: Consecutive patients with persistent or recurrent macular edema (central macula thickness >250 µm) due to RVO were enrolled in this prospective study. Study eyes received intravitreal injections of ziv-aflibercept (1.25 mg/0.05 mL) at baseline. Patients were reassessed monthly for 4 months and given additional injections pro re nata for worsening best-corrected visual acuity (BCVA), intraretinal edema or subretinal fluid seen on spectral domain optical coherence tomography, or central macular thickness (CMT) measurements >250 µm. The primary endpoint was improvement in mean CMT at 4 months. Secondary endpoints included improvement in mean BCVA, and ocular and systemic safety signals. Results: Nine eyes (five central and four branch RVOs) of nine patients were enrolled. The mean ± standard deviation CMT decreased from 604±199 µm at baseline to 319±115 µm (P=0.001) at 1 month and to 351±205 µm (P=0.026) at 4 months. The mean BCVA did not improve significantly from baseline (1.00 LogMAR) to the 1-month (0.74 LogMAR; P=0.2) and 4-month (0.71 LogMAR; P=0.13) visits. No safety signals were noted. Conclusion: In this small prospective study, intravitreal ziv-aflibercept significantly improved mean CMT in eyes with persistent or recurrent macular edema due to RVOs. Prospective, randomized trials comparing ziv-aflibercept with standard pharmacotherapy are needed to better define efficacy and safety. Keywords: ziv-aflibercept, retinal vein occlusion, cystoid macular edema |
topic |
ziv-aflibercept retinal vein occlusion cystoid macular edema |
url |
https://www.dovepress.com/intravitreal-ziv-aflibercept-for-macular-edema-following-retinal-vein--peer-reviewed-article-OPTH |
work_keys_str_mv |
AT pauloser intravitrealzivafliberceptformacularedemafollowingretinalveinocclusion AT chhablanij intravitrealzivafliberceptformacularedemafollowingretinalveinocclusion AT dedhiacj intravitrealzivafliberceptformacularedemafollowingretinalveinocclusion AT stewartmw intravitrealzivafliberceptformacularedemafollowingretinalveinocclusion AT mansouram intravitrealzivafliberceptformacularedemafollowingretinalveinocclusion |
_version_ |
1725348871682392064 |